We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Actinium

News List

Actinium Completes Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial americanpharmaceuticalreview
April 02, 2021
Actinium Pharmaceuticals announced that initial patient enrollment in the second dose cohort in the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial in fit and unfit patients with relapsed or refractory Acute Myeloid Leukemia ...
Actinium Initiates Patient Enrollment in Iomab-ACT Trial americanpharmaceuticalreview
April 01, 2021
Actinium Pharmaceuticals announced its collaborator, Memorial Sloan Kettering Cancer Center (MSK), has commenced patient enrollment in the Phase 1 study evaluating Iomab-ACT for targeted conditioning prior to treatment with MSK's CD19 targeted ...
Actinium Announces Actimab-A Plus 7+3 Combination Trial for AML americanpharmaceuticalreview
March 05, 2020
Actinium Pharmaceuticals is expanding its CD33 program studying Actimab-A into a combination trial with the chemotherapy regimen 7+3 in patients with newly diagnosed acute myeloid leukemia (AML) ...
Actinium, Astellas Form Research Partnership contractpharma
March 30, 2018
Actinium Pharmaceuticals has entered into a research and option agreement with Astellas to develop Actinium-225 Radio-Conjugates (ARCs) using its Actinium Warhead Enabling (AWE) Platform Technology.